Request Trial
artco-shutterstock-com
Artco / Shutterstock.com
9 November 2016Americas

Philips and Masimo agree $300m deal, end patent disputes

Philips has agreed to make a $300 million cash payment in a multi-year partnership with Masimo, a health technology company.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Masimo convinces judge that Apple took secrets—but it’s not enough
19 March 2026   Although the court agreed that the tech giant misappropriated some of Masimo’s information related to pulse oximetry technology, Apple is not barred from using it, says a California judge.
Americas
J&J unit targets former employee over alleged mass data theft
17 March 2026   Janssen seeks injunctive relief after a forensic review uncovers mass downloads of trade secrets spanning oncology, neuroscience and immunology portfolios.
Americas
Mylan withdraws defence claims against Novo in Wegovy dispute
13 March 2026   A proposed judgment by the rivals would extend the period in which Mylan is barred from obtaining regulatory approval for its generic of the weight-loss injectable.


Editor's picks

Masimo convinces judge that Apple took secrets—but it’s not enough
Americas
Masimo convinces judge that Apple took secrets—but it’s not enough
19 March 2026

Editor's picks

Americas
Masimo convinces judge that Apple took secrets—but it’s not enough
19 March 2026

More features

Ozempic goes generic as Novo’s key patent expires
Masimo convinces judge that Apple took secrets—but it’s not enough
Sandoz strikes fresh biosimilar deal with South Korean biotech
US firm boosts patent bench with Desmarais hire
J&J unit targets former employee over alleged mass data theft
HSF Kramer hires patent litigator as partner in Germany
INTA: ‘New normal’ for in-house counsel as budgets fall
Mylan withdraws defence claims against Novo in Wegovy dispute